Lee Honigberg - Senior Scientist and Associate Director, OMNI Biomarker Development

Lee Honigberg

Senior Scientist and Associate Director, OMNI Biomarker Development

"Genentech is a great place to do drug development – we test novel therapeutics for serious diseases and take an integrated approach to clinical development that is driven by a strong commitment to scientific integrity."
8
Years at Genentech
6
Publications

I did my PhD in Neuroscience at UCSF and then started at a small company using C. elegans to discover new drug targets for neuropathic pain. That company was subsequently acquired by Celera Genomics where I continued to work in drug discovery across several therapeutic areas. After Celera, I moved further toward the clinic, leading the preclinical and biomarker development for a Btk inhibitor at Pharmacyclics. I joined Genentech in 2009 to return to Neuroscience and focus on biomarkers.

Featured Publication

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

Mol Neurodegener. 2014; 9: 22. Published online 2014 Jun 6.

Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA.